 NORTH BILLERICA, Mass.--BUSINESS WIRE--Lantheus Holdings, Inc. NASDAQ: LNTH Lantheus announced today that its subsidiary, EXINI Diagnostics AB, was granted 510k clearance by the U.S. Food and Drug Administration FDA for its digital application, aPROMISETM automated PROstate Cancer Molecular Imaging Standardized Evaluation. Clinicians will have the option to utilize aPROMISE with PYLARIFY piflufolastat F 18 to increase the efficiency and reproducibility of their PSMA PETCT assessm 